Esophageal adenocarcinoma · 5 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
CLF Variant #04 | — | R 12 568 | 42d | — | — | — | — | 1 |
ECX Variant #01 | — | R 2 313 | 21d | — | 30.6 mo | — | — | 3 |
Cisplatin and Fluorouracil (CF) Variant #29 | — | R 1 900 | 21d | — | 23.4 mo | — | — | 2 |
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug | — | R 743 | 42d | ~3.8 mo | ~13.9 mo | ~3 | ~R 2 230 PFS proxy · indirect | 2 |
No neoadjuvant therapy Partial | — | — | — | — | ~19.2 mo | — | — | 8 |
5 of 5 regimens shown